IP Verse

A New Use For Deferiprone - EP1294379

The patent EP1294379 was granted to Apotex on Apr 1, 2009. The application was originally filed on Jun 28, 2001 under application number EP01949158A. The patent is currently recorded with a legal status of "Revoked".

EP1294379

APOTEX
Application Number
EP01949158A
Filing Date
Jun 28, 2001
Status
Revoked
May 14, 2021
Grant Date
Apr 1, 2009
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LIPOMEDFeb 11, 2020CIESLAINTERVENTION ADMISSIBLE
LIPOMEDDec 24, 2009CIESLAADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTGB2118176

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- HERSHKO C ET AL, "IRON MOBILIZATION FROM MYOCARDIAL CELLS BY 3 HYDROXYPYRIDIN-4-ONE CHELATORS STUDIES IN RAT HEART CELLS IN CULTURE", BLOOD, (1991), vol. 77, no. 9, ISSN 0006-4971, pages 2049 - 2053, XP001030512 [X] 1-48 * page 2049, column L, lines 1-35 * * page 2050, column R, lines 1-20 * * tables 1,2 * * page 2051, column R, lines 3-12 * * page 2052, column R, lines 19-30 *-
INTERNATIONAL-SEARCH-REPORT- OLIVIERI N F ET AL, "Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassemia major during long-term therapy with the orally active iron chelating agent L1.", BLOOD, Abstracts Submitted to the 36th Annual Meeting of the American Society of Hematology;Nashville, Tennessee, USA; December 2-6, 1994, (1994), vol. 84, no. 10 SUPPL. 1, ISSN 0006-4971, page 109A, XP001030511 [X] 1-48 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- OLIVIERI N.F. ET AL, "Reduction of tissue iron stores and normalization of serum ferritin durin treatment with the oral iron chelator L1 in thalassemia intermedia.", BLOOD, (1992) 79/10 (2741-2748)., XP001030506 [X] 1-48 * abstract * * page 2741, column L, line 1 - column R, line 13 * * page 2742, column L, lines 33-37 * * page 2742, column R, lines 24-53 * * page 2473, column R, lines 9-30 * * page 2743, column R, lines 3-10 * * figure 3 * * page 2747, column L, line 11 - column R, line 5 *-
INTERNATIONAL-SEARCH-REPORT- LINK GABRIELA ET AL, "Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells.", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, (199902), vol. 133, no. 2, ISSN 0022-2143, pages 179 - 188, XP001024997 [X] 1-48 * abstract * * page 179, column L, line 1 - column R, line 14 * * page 181, column R, line 15 - page 182, column R, line 11 * * figures 2-4 * * page 184, column L, lines 8-16 * * page 185, column L, line 14 - page 186, column R, line 22 *
INTERNATIONAL-SEARCH-REPORT- DIAV-CITRIN O ET AL, "Oral iron chelation with deferiprone.", PEDIATRIC CLINICS OF NORTH AMERICA, (1997 FEB) 44 (1) 235-47. REF: 75, XP001030553 [X] 1-50 * page 239, paragraphs 5-7 * * Summary; page 242 - page 243 *
INTERNATIONAL-SEARCH-REPORT- MODELL B ET AL, "Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register", LANCET, XX, XX, (20000610), vol. 355, no. 9220, ISSN 0140-6736, pages 2051 - 2052, XP004263666 [X] 1-50 * page 2051, column L, lines 1-10 * * page 2051, column R, lines 32-46 *
INTERNATIONAL-SEARCH-REPORT- ANDERSON LISA ET AL, "Improved cardioprotection with the oral iron-chelator L1, over standard therapy with subcutaneous deferoxamine in iron overload cardiomyopathy.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 50th Annual Scientific Session of the American College of Cardiology;Orlando, Florida, USA; March 18-21, 2001, (200102), vol. 37, no. 2 Supplement A, ISSN 0735-1097, page 218A, XP001030545 [XP] 1-48 * abstract *
INTERNATIONAL-SEARCH-REPORT- WONKE, B. (1) ET AL, "Combined therapy with deferiprone and desferrioxamine.", BRITISH JOURNAL OF HAEMATOLOGY, ( NOV., 1998 ) VOL. 103, NO. 2, PP. 361-364., XP001030537 [X] 1-50 * page 361, column L, line 19 - column R, line 8 * * page 362, column R, lines 8-22 * * page 363, column R, lines 19-53 *
INTERNATIONAL-SEARCH-REPORT- OLIVIERI N.F. ET AL, "Long-term trials of deferiprone in Cooley's anemia.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998) 850/- (217-222)., XP001030503 [X] 1-48 * abstract * * page 217, lines 1-3 * * page 217, line 16 - page 218, line 2 * * page 219, lines 1-9 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents